A pharmaceutical giant is lobbying the province on drug access and innovative medicines, only months after Premier Doug Ford used a gathering of his provincial and territorial colleagues to muster support for speeding up approvals of life-saving medications and treatments.
Gilead Sciences Canada, Inc was registered this past week by Sarah Letersky, a consultant with Rubicon Strategy.
According to her registration with the integrity commissioner's office, Gilead wants to talk to officials about innovative medicines and impact on drug access and timelines, and post-pandemic recovery plans, "specifically related to liver disease management, cancer, cell therapy implementation, HIV prevention and control and system impact and efficiency in screening and testing."